Literature DB >> 11958284

Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats.

H T Lee1, Y J Lee, S J Chung, C K Shim.   

Abstract

To investigate the effect of two prokinetic drugs, cisapride and metoclopramide, on the bioavailability of drugs, a marker drug, ranitidine, was administered to healthy volunteers following pre-treatments with or without the prokinetic agents. Cisapride or metoclopramide HCl (a respective dose of 10 mg) was administered orally 30 min prior to an oral administration of ranitidine (300 mg). Serum samples were collected for a 12 h period after the administration of ranitidine and the concentration of ranitidine was determined by an HPLC method. The bioavailability parameters of the groups with the prokinetic agent pretreatment were compared with those of the control group. In addition, the effects of these prokinetic drugs on the in vitro apparent permeability of ranitidine across the rat jejunum in the Ussing chamber, and on the in vivo intestinal transit of charcoal meals in rats were also examined. The Tmax of ranitidine in human subjects was shortened significantly by the either of the pretreatments (i.e., with cisapride and metoclopramide). The AUC(inf) of ranitidine in human subjects was also decreased significantly in the case of cisapride pretreatment. However, no changes were observed for the values of Cmax and T(1/2) by the pretreatments. Rat studies revealed that cisapride and metoclopramide had no influence on the in vitro permeability of ranitidine or the in vivo intestinal transit of charcoal meals. Therefore, these data indicated that the changes in the bioavailability parameters (i.e., Tmax and AUC(inf)) in humans are not related with the intestinal permeability or intestinal transit of ranitidine. The shortened Tmax of ranitidine appears to be due to accelerated gastric emptying of the drug. However, underlying mechanisms for the decreased AUC(inf) of ranitidine in the case of cisapride pretreatment are currently unclear.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11958284

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  4 in total

1.  Exploration of Antiemetics for Osteoporosis Therapy-Induced Nausea and Vomiting Using PET Molecular Imaging Analysis to Gastrointestinal Pharmacokinetics.

Authors:  Tomotaka Shingaki; Yumiko Katayama; Takayoshi Nakaoka; Tadayuki Takashima; Kayo Onoe; Takashi Okauchi; Emi Hayashinaka; Yasuhiro Wada; Yilong Cui; Yasuyoshi Watanabe
Journal:  Pharm Res       Date:  2016-02-11       Impact factor: 4.200

2.  Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan.

Authors:  Shaheen Perveen; Shahnaz Gauhar; Rabia Ismail Yousuf; Huma Ali; Farya Zafar; Anab Fatima Sheikh
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

Review 3.  Gastric function measurements in drug development.

Authors:  Thorsten Pohle; Wolfram Domschke
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

Review 4.  Pharmacokinetic drug-drug interaction and their implication in clinical management.

Authors:  Caterina Palleria; Antonello Di Paolo; Chiara Giofrè; Chiara Caglioti; Giacomo Leuzzi; Antonio Siniscalchi; Giovambattista De Sarro; Luca Gallelli
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.